For the quarter ending 2026-03-31, OVID has $225,628K in assets. $27,359K in debts. $94,064K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 94,064 | 13,153 | 20,611 | 28,415 |
| Marketable securities | 61,458 | 56,482 | 4,992 | 9,932 |
| Prepaid expenses and other current assets | 4,623 | 4,733 | 3,221 | 3,742 |
| Total current assets | 160,145 | 74,368 | 28,824 | 42,089 |
| Marketable securities - noncurrent | 10,076 | 20,812 | - | - |
| Long-term equity investments | 41,961 | 41,961 | 20,908 | 20,908 |
| Restricted cash | 1,931 | 1,931 | 1,931 | 1,931 |
| Other assets | - | 0 | 0 | 0 |
| Right-of-use asset, net | 11,298 | 11,610 | 11,916 | 12,215 |
| Property and equipment, net | 217 | 252 | 269 | 285 |
| Total assets | 225,628 | 150,934 | 63,848 | 77,428 |
| Deferred revenue | - | - | 718 | 718 |
| Accounts payable | 8,876 | 1,956 | 1,710 | 3,950 |
| Accrued expenses | 5,413 | 4,899 | 2,959 | 2,872 |
| Current portion, lease liability | 1,459 | 1,433 | 1,409 | 1,384 |
| Total current liabilities | 15,748 | 8,288 | 6,796 | 8,924 |
| Lease liability | 11,611 | 11,986 | 12,354 | 12,715 |
| Total liabilities | 27,359 | 20,274 | 19,150 | 21,639 |
| Common stock, 0.001 par value 315,000,000 shares authorized 167,266,466 and 130,184,353 shares issued and outstanding at march31, 2026 and december31, 2025, respectively | 167 | 130 | 71 | 71 |
| Additional paid-in-capital | 537,225 | 452,445 | 376,129 | 375,005 |
| Accumulated other comprehensive loss | -422 | -202 | -126 | -69 |
| Accumulated deficit | -338,701 | -321,713 | -331,376 | -319,218 |
| Total stockholders equity | 198,269 | 130,660 | 44,698 | 55,789 |
| Total liabilities and stockholders equity | 225,628 | 150,934 | 63,848 | 77,428 |
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)